Dataset Viewer
pbs_code
stringclasses 390
values | drug
stringclasses 18
values | brand
stringclasses 32
values | formulation
stringclasses 38
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
float64 9.19k
16.9k
⌀ | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | maximum_prescribable_pack
float64 1
5
| maximum_quantity_units
float64 1
180
| number_of_repeats
float64 0
6
| schedule_code
stringdate 2025-07-01 00:00:00
2025-08-01 00:00:00
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 2
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10056G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10056G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10056G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10056G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10058J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10060L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10060L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10060L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10060L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10064Q
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10064Q
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10064Q
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10064Q
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10068X
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10068X
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10068X
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10068X
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10071C
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10072D
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10073E
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10077J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10077J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10077J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10077J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10078K
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10079L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10079L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10079L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10079L
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10081N
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
juvenile idiopathic arthritis
|
Continuing Treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
10137M
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10137M
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10238W
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10238W
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10511F
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 5 |
2025-07
| 2,025 |
JULY
|
10511F
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 5 |
2025-07
| 2,025 |
JULY
|
10517M
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 3 |
2025-07
| 2,025 |
JULY
|
10517M
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 3 |
2025-07
| 2,025 |
JULY
|
10517M
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 3 |
2025-07
| 2,025 |
JULY
|
10517M
|
Tofacitinib
|
Xeljanz
|
Tablet 5 mg
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 56 | 3 |
2025-07
| 2,025 |
JULY
|
10767Q
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 1 |
2025-07
| 2,025 |
JULY
|
10767Q
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 1 |
2025-07
| 2,025 |
JULY
|
10774C
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10774C
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10774C
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10774C
|
Ustekinumab
|
Stelara
|
Injection 45 mg in 0.5 mL
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10890E
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10890E
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10890E
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10892G
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
10893H
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10894J
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 8 | 0 |
2025-07
| 2,025 |
JULY
|
10894J
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 8 | 0 |
2025-07
| 2,025 |
JULY
|
10894J
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 8 | 0 |
2025-07
| 2,025 |
JULY
|
10895K
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
10895K
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
10896L
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
10897M
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
10898N
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 2 |
2025-07
| 2,025 |
JULY
|
10899P
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10899P
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
10900Q
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10900Q
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10900Q
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 4 | 4 | 0 |
2025-07
| 2,025 |
JULY
|
10901R
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
10904X
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10904X
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10904X
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
ankylosing spondylitis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10905Y
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10905Y
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 143
Size of downloaded dataset files:
43.9 kB
Size of the auto-converted Parquet files:
43.9 kB
Number of rows:
3,454